New study supports painkiller glucosamine

19 February 2007

The natural supplement glucosamine is just as effective as the non-steroidal anti-inflammatory painkiller paracetamol in the treatment of osteoathritis, according to trial data published in Arthritis and Rheumatism. The double-blind, randomized, placebo-controlled study featured 318 patients some of whom were given 1,500mg of the nutrient.

Since glucosamine is a precursor for glycosaminoglycans, a major component of joint cartilage, the current consensus is that supplemental glucosamine may help to rebuild cartilage and treat arthritis. Commenting on the recent data, Olivier Bruyere, of the University of Liege in Belgium, said that "the results support existing research and highlight the importance of glucosamine as a treatment for osteoarthritis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight